COMMUNIQUÉS West-GlobeNewswire

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
05/05/2025
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and [...]
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
05/05/2025
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high [...]
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
05/05/2025
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent [...]
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
05/05/2025
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre- [...]
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
05/05/2025
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05 [...]
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
05/05/2025
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
05/05/2025
The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and [...]
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
05/05/2025
Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc [...]
Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
05/05/2025
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene [...]
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
05/05/2025
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first [...]
MediWound to Report First Quarter 2025 Financial Results
05/05/2025
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic [...]
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
05/05/2025
-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( [...]
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
05/05/2025
LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a [...]
Hydreight Technologies Appoints Dr. Roebuck As a Director of the Company
05/05/2025
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (" Hydreight " or the " Company "), a North American, fully integrated, mobile clinical [...]
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
05/05/2025
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
4DMT to Participate in Upcoming Investor Conferences
05/05/2025
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
05/05/2025
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - - Findings offer a more detailed understanding of WTX-921’s anti-inflammatory [...]
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025
05/05/2025
LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025 [...]
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
05/05/2025
HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]

Pages